S G O'Brien

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Andreas Hochhaus, S G O'Brien, François Guilhot et al. · Leukemia · 2009 · 842 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +7

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

S G O'Brien, P Meinhardt, Epperson E. Bond et al. · British Journal of Cancer · 2003 · 154 citations · Full text

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

David Marín, Sarah Marktel, M Bua et al. · Leukemia · 2003 · 71 citations

Chronic Phase, Prognostic Factors, Hematological Malignancy +9

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

E. Feldman, Jörge E. Cortes, Daniel J. DeAngelo et al. · Leukemia · 2008 · 60 citations

Hematological Malignancy, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome +8

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

François Guilhot, Brian Druker, Richard A. Larson et al. · Haematologica · 2009 · 49 citations · Full text